首页 > 师资队伍 > 副教授副教授
陆小云
发布时间:2016-06-02

   女,博士,副教授、硕士生导师,广东省杰出青年基金获得者,863青年科学家项目获得者,广东省特支计划青年拔尖人才,广州市珠江新星。2005年6月毕业于中国药科大学制药工程专业,获学士学位;2010年6月毕业于中国药科大学药物化学专业,获理学博士学位;2010年7月-2016年2月在中国科学院广州生物医药与健康研究院从事科研工作,2012年1月被聘为副研究员;2016年3月加入暨南大学药学院,从事教学科研工作。

    从事创新药物先导化合物的发现研究。主要瞄准肺部疾病(肺癌和结核病等)临床耐药问题,设计和合成具有重要生物学功能和良好成药性的先导化合物,为创新药物开发奠定基础。现主持863青年科学家项目,广东省杰出青年项目,广东省特支计划青年拔尖人才和广州市珠江新星等研究课题。已在Angew. Chem. Int. Ed.和J. Med. Chem 等重要专业期刊发表第一作者或通讯作者SCI论文23篇,申请发明专利16项(授权4项,PCT 2项),部分专利已实现转移转化。曾获中国药学会-施维雅药物化学奖,中科院卢嘉锡青人才奖等奖项。

 

主要研究方向: 

 1. 新型抗肺癌成药性先导化合物的研究   

 2. 克服临床耐药的新型抗结核药物研究

 3. 其他新型激酶类抑制剂的设计研究

 

近五年内发表的代表性论文:

1. Xiaokai Li#, Jiayi Shen#, Li Tan#, Zhang Zhang, Donglin Gao, Jinfeng Luo , Huimin Cheng, Xiaoping Zhou, Jie Ma, Ke Ding*, Xiaoyun Lu* , Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-RafV600E inhibitors. Bioorg Med Chem Lett. 2016, 26, 2760–2763

2. Xiaoyun Lu#*, Zhang Zhang#, xiaomei Ren, Xiaofen Pan, Deping Wang , Xiaoxi Zhuang , Jinfeng Luo , Rongmin Yu, Ke Ding*. Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. Bioorg Med Chem Lett. 2015,25,3458-63.

3. Jian Tang  Bangxing Wang, Tian Wu, Junting Wan , Zhengchao Tu , Moses Njire, Baojie Wan, Scott G. Franzblauc, Tianyu Zhang*, Xiaoyun Lu *, and Ke Ding *. Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents. ACS Med. Chem. Lett. 2015, 6 (7), 814–818.

4. Yupeng Li#, Xiaoyun Lu#, Xiaomei Ren* and Ke Ding*. Small Molecule Discoidin Domain Receptor Kinase Inhibitors and Potential Medical Applications. J. Med. Chem. 2015, 58, 32873301.

5. Lei Yu, Zhen Wang, Zhang Zhang, Xiaomei Ren, Xiaoyun Lu*, and Ke Ding*.  Small-Molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential. Curr Top Med Chem, 2015, 15, 776-794.

6. Xiaoyun Lu*, Jian Tang, Qidong You, Baojie Wan and Scott G. Franzblau. Design, Synthesis and Antitubercular Evaluation of New 2-amino-5-(4-(benzyloxy)benzyl)thiophene-3-carboxylic Acid Derivatives. Part 3. Lett Drug Des & Discov, 2015, 12, 29-37.

7. Xiaoyun Lu*, Jian Tang, Zhang Zhang and Ke Ding*. Bacterial β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) as a Target for Novel Antibacterial Agents Design. Curr Med Chem, 2015, 22, 651-667

8. Tianfeng Xu#, Lianwen Zhang#, Shilin Xu, Chao-Yie Yang, Jinfeng Luo, Fang Ding, Xiaoyun Lu*, Yingxue Liu, Zhengchao Tu, Duanqing Pei, Honglin Li, Xiaomei Ren, Shaomeng Wang, Meiyu Geng, Jian Ding, and Ke Ding*. Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants. Angew. Chem. Int. Edit., 2013, 52, 8387-8390.

9. Xiaoyun Lu and Ke Ding*. Novel Anaplastic Lymphoma Kinase nhibitors Targeting Clinically Acquired Resistance. J. Med. Chem., 2014, 57, 1167-1169.

10. Xiaoyun Lu*, Man Lv, Kun Huang, Ke Ding and Qidong You*. Pharmacophore and Molecular Docking Guided 3D-QSAR Study of Bacterial Enoyl-ACP Reductase (FabI) Inhibitors. Int. J. Mol. Sci., 2012, 13, 6620-6638.

11. Xiaoyun Lu, Xiaobo Liu, Baojie Wan, Scott G. Franzblau, Lili Chen, Changlin Zhou, Qidong You*. Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2. Euro. J. Med. Chem., 2012, 49, 164-171.

 

电话: 020-85221523

联系方式: E-mail: luxy2016@jnu.edu.cn